<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00062036</url>
  </required_header>
  <id_info>
    <org_study_id>030162</org_study_id>
    <secondary_id>03-C-0162</secondary_id>
    <secondary_id>NCI-5855</secondary_id>
    <secondary_id>CDR0000304438</secondary_id>
    <nct_id>NCT00062036</nct_id>
    <nct_alias>NCT00059163</nct_alias>
  </id_info>
  <brief_title>Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>Tumor Infiltrating Lymphocytes (TIL Cells) Transduced With An Interleukin-2 (SBIL-2) Gene Following The Administration Of A Nonmyeloablative But Lymphocyte Depleting Regimen in Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as cyclophosphamide and fludarabine use different&#xD;
      ways to stop tumor cells from dividing so they stop growing or die. Inserting the gene for&#xD;
      interleukin-2 into a person's tumor infiltrating lymphocytes may make the body build an&#xD;
      immune response to kill tumor cells. Combining cyclophosphamide and fludarabine with&#xD;
      gene-modified tumor cells may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of gene-modified&#xD;
      tumor infiltrating lymphocytes when given together with cyclophosphamide and fludarabine and&#xD;
      to see how well they work in patients with metastatic melanoma (phase I is closed to accrual&#xD;
      3/29/06).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the survival of patients with metastatic melanoma administered interleukin-2&#xD;
           gene-modified tumor infiltrating lymphocytes after cyclophosphamide and fludarabine.&#xD;
&#xD;
        -  Compare survival results with prior Surgery Branch studies using adoptive cell therapy&#xD;
           without the interleukin-2 retroviral vector (SBIL-2) gene.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine clinical tumor regression in patients administered interleukin-2 gene-modified&#xD;
           TIL after cyclophosphamide and fludarabine followed by interleukin-2.&#xD;
&#xD;
        -  Determine the toxicity profile of this regimen in these patients.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Phase I (closed to accrual as of 3/29/06):&#xD;
&#xD;
             -  Harvest: TIL are harvested, transduced with IL-2 gene, and expanded in vitro over a&#xD;
                period of approximately 4 weeks.&#xD;
&#xD;
             -  Nonmyeloablative preparative regimen (chemotherapy): Patients receive&#xD;
                cyclophosphamide IV over 1 hour on days -7 and -6 and fludarabine IV over 30&#xD;
                minutes on days -5 to -1.&#xD;
&#xD;
             -  Lymphocyte administration: Patients receive IL-2 gene-transduced TIL IV over 20-30&#xD;
                minutes on day 0. They also receive high-dose IL-2 IV over 15 minutes every 8 hours&#xD;
                on days 0 -5 (maximum 15 doses). Beginning 1-2 days after lymphocyte&#xD;
                administration, patients receive filgrastim (G-CSF) subcutaneously (SC) daily, ,&#xD;
                until blood counts recover.&#xD;
&#xD;
             -  Retreatment: Patients are re-evaluated every 4-6 weeks. Retreatment depends on&#xD;
                disease status after each regimen. Patients with dose-limiting toxicity do not&#xD;
                receive further treatment.&#xD;
&#xD;
                  -  No response: Patients with stable disease or disease progression after the&#xD;
                     initial treatment are followed or removed from the study.&#xD;
&#xD;
                  -  Partial response: Patients with a partial or minor response after the initial&#xD;
                     treatment may receive retreatment, approximately 2-4 weeks later, with&#xD;
                     chemotherapy, IL-2 gene-transduced TIL, immunization, and high-dose IL-2 as&#xD;
                     above, every 4-6 weeks for up to 2 courses provided at least a partial&#xD;
                     response is documented after each regimen.&#xD;
&#xD;
                  -  Complete response: Patients with a complete response receive no further&#xD;
                     treatment.&#xD;
&#xD;
        -  Phase II: Patients receive treatment and retreatment as in phase I with the MTD of IL-2&#xD;
           gene-transduced TIL.&#xD;
&#xD;
      Patients are followed every 3-6 weeks in the absence disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 33 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical tumor regression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>interleukin-2 gene</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic tumor infiltrating lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of melanoma&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
               -  Refractory to standard therapy including high-dose interleukin-2 (IL-2) therapy&#xD;
&#xD;
          -  Evaluable disease&#xD;
&#xD;
          -  Patients may enroll at the cell infusion stage provided they have tumor available for&#xD;
             biopsy OR expandable SBIL-2-transduced tumor infiltrating lymphocytes available&#xD;
&#xD;
          -  Progressive disease during prior immunization to melanoma antigens or cellular&#xD;
             therapy, with or without myeloablation, allowed&#xD;
&#xD;
          -  Symptomatic CNS lesions allowed provided immediate active treatment for symptomatic&#xD;
             lesions has been completed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,000/mm^3&#xD;
&#xD;
          -  WBC greater than 3,000/mm^3&#xD;
&#xD;
          -  Lymphocyte count greater than 500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 8.0 g/dL&#xD;
&#xD;
          -  No coagulation disorder&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL (less than 3.0 mg/dL in patients with Gilbert's&#xD;
             syndrome)&#xD;
&#xD;
          -  AST/ALT less than 3 times upper limit of normal&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C virus negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.6 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No myocardial infarction&#xD;
&#xD;
          -  No cardiac arrhythmias&#xD;
&#xD;
          -  No abnormal stress thallium or comparable test&#xD;
&#xD;
          -  LVEF &gt; 45% and normal stress cardiac test in patients with the following criteria:&#xD;
&#xD;
               -  50 years old or greater&#xD;
&#xD;
               -  History of EKG abnormalities, symptoms of cardiac ischemia or arrhythmias&#xD;
&#xD;
          -  No major cardiovascular illness&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No obstructive or restrictive pulmonary disease&#xD;
&#xD;
          -  No major respiratory illness&#xD;
&#xD;
          -  FEV_1 &gt; 60% predicted in patients with prolonged history of cigarette smoking or&#xD;
             symptoms of respiratory dysfunction&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No prior severe immediate hypersensitivity reaction&#xD;
&#xD;
          -  No primary or secondary immunodeficiency&#xD;
&#xD;
          -  No active systemic infection&#xD;
&#xD;
          -  No concurrent opportunistic infection&#xD;
&#xD;
          -  No major immune system illness&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 4 months after study&#xD;
             therapy&#xD;
&#xD;
          -  Must sign a durable power of attorney&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior anti-cytotoxic T-lymphocyte antibody-4 antibody (CTLA-4) allowed unless&#xD;
             post-MDX010 treatment and colonoscopy with colonic biopsies are normal&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent steroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior systemic therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A. Rosenberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCI - Center for Cancer Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>June 5, 2003</study_first_submitted>
  <study_first_submitted_qc>June 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2003</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <name_title>Steven A. Rosenberg, M.D./National Cancer Institute</name_title>
    <organization>National Institutes of Health</organization>
  </responsible_party>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

